2,237 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Values First Advisors Inc.

Values First Advisors Inc. purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,237 shares of the company’s stock, valued at approximately $57,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Profund Advisors LLC increased its stake in BridgeBio Pharma by 1.1% in the second quarter. Profund Advisors LLC now owns 51,029 shares of the company’s stock valued at $1,293,000 after purchasing an additional 555 shares during the last quarter. American International Group Inc. boosted its stake in BridgeBio Pharma by 1.0% in the first quarter. American International Group Inc. now owns 57,491 shares of the company’s stock valued at $1,778,000 after acquiring an additional 565 shares in the last quarter. Bfsg LLC grew its holdings in shares of BridgeBio Pharma by 175.6% during the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of BridgeBio Pharma by 17.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after purchasing an additional 801 shares during the last quarter. Finally, Amalgamated Bank grew its stake in BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after buying an additional 962 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Price Performance

BBIO opened at $23.84 on Friday. The stock’s 50 day simple moving average is $26.11 and its 200 day simple moving average is $26.53. The stock has a market cap of $4.46 billion, a P/E ratio of -7.40 and a beta of 1.08. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.61. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $3.96 million. BridgeBio Pharma’s quarterly revenue was up 32.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. Research analysts expect that BridgeBio Pharma, Inc. will post -2.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $676,234.41. Following the transaction, the chief executive officer now owns 4,897,443 shares of the company’s stock, valued at approximately $120,917,867.67. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Neil Kumar sold 27,389 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $676,234.41. Following the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at $120,917,867.67. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $102,586.95. Following the transaction, the chief financial officer now directly owns 85,192 shares in the company, valued at approximately $2,103,390.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,831,544 shares of company stock worth $150,128,821 in the last ninety days. Insiders own 24.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BBIO. Piper Sandler began coverage on shares of BridgeBio Pharma in a report on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 target price on the stock. Leerink Partners lowered their price target on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Evercore ISI lowered their target price on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a report on Monday, September 16th. Finally, Scotiabank assumed coverage on shares of BridgeBio Pharma in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $44.00 price objective for the company. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.50.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.